Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction

Erectile Dysfunction Clinical Trial

Official title:

Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-dose, Double-blind, Randomized Multi-center Trial - POTENT I

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00631969
• Other study ID #: 12093
• Secondary ID: 2008-000536-40
• Status: Completed
• Phase: Phase 3
• First received: February 29, 2008
• Last updated: December 8, 2014
• Start date: April 2008
• Est. completion date: January 2009

Study information

• Verified date: December 2014
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study investigates the safety and efficacy of a new dosage form of Vardenafil, an orodispersible tablet (ODT), and compares it to the safety and efficacy of a placebo (inactive) tablet in the treatment of erectile dysfunction. After a 4-week unmedicated phase, patients will receive Vardenafil ODT or matching placebo for 12 weeks. Safety will be determined by laboratory and other evaluations. Efficacy will be determined by the results of different questionnaires and the patient diary that will be used.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 362
• Est. completion date: January 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males 18 years-of-age or older

• Stable, heterosexual relationship for at least 6 months

• A history of erectile dysfunction (ED) for at least 6 months

Exclusion Criteria:

• Any underlying cardiovascular condition, including unstable angina pectoris

• History of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to visit 1

• Uncontrolled atrial fibrillation / flutter at screening

• History of surgical prostatectomy for prostate cancer

• Hereditary degenerative retinal disorders

• History of loss of vision because of Non-arteritic anterior ischemic optic neuropathy (NAION), temporary or permanent loss of vision

• Presence of penile anatomical abnormalities

• Subjects who have been confirmed with phenylketonuria (PKU)

• Spinal cord injury

• Resting or postural hypotension or hypertension

• Subjects who are taking nitrates or nitric oxide donors, androgens, anti-androgens, alpha- blockers, medication known to prolong QT interval, Human immunodeficiency virus (HIV) protease inhibitors, itraconazole or ketoconazole, an clarithromycin and erythromycin

• Use of any treatment for ED within 7 days of Visit 1

• History of congenital QT prolongation

• History of syncope within the last 6 months prior to entry into the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Erectile Dysfunction

Intervention

Drug:
• Vardenafil ODT (STAXYN, BAY38-9456)
Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
• Placebo
Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Bayer	GlaxoSmithKline, Schering-Plough

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Netherlands,  South Africa,  Spain, 

References & Publications (4)

Debruyne FM, Gittelman M, Sperling H, Börner M, Beneke M. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J Sex Med. 2011 Oct;8(10):2912-23. doi: 10.1111/j.1 — View Citation

Heinig R, Weimann B, Dietrich H, Böttcher MF. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials. Clin Drug Investig. 2011;31(1):27-41. doi: 10.2165/11584950-000000000-00000. — View Citation

Sperling H, Debruyne F, Boermans A, Beneke M, Ulbrich E, Ewald S. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med. 2010 Apr;7(4 Pt 1):1497-507. doi: 10.111 — View Citation

Sperling H, Gittelman M, Norenberg C, Ulbrich E, Ewald S. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or LOCF	The primary variable was the treatment group difference from baseline to Week 12 or Last observation carried forward (LOCF) of the least square mean difference in the IIEF-EF domain score (1-30 ordinal points, specifying the severity of erectile dysfunction: <=10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; >25 'no ED').	from baseline up to 12 weeks	No
Primary	Change in Percentage From Baseline in Success of Penetration at 12 Weeks	Sexual encounter profile (SEP) items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to penetrate the partner.	from baseline up to 12 weeks of treatment	No
Primary	Change From Baseline in Success of Erection Maintenance at 12 Weeks	SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to maintain an erection after penetration.	from baseline up to 12 weeks of treatment	No
Secondary	Percentage of Subjects Achieving "Back to Normal" Erectile Function	Responders: percentage of subjects achieving an IIEF-EF score > 25. The primary variable was the treatment group difference from baseline to Week 12 or Last observation carried forward (LOCF) of the least square mean difference in the IIEF-EF domain score (1-30 ordinal points, specifying the severity of erectile dysfunction: <=10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; >25 'no ED').	up to 12 weeks of treatment	No
Secondary	Change in Percentage From Baseline in Ability to Obtain an Erection at 12 Weeks	SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to obtain successful erections.	from baseline up to 12 weeks of treatment	No
Secondary	Change in Percentage From Baseline in Satisfaction With the Hardness of Erection at 12 Weeks	SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to get satisfactory hardness of erections.	from baseline up to 12 weeks of treatment	No
Secondary	Change in Percentage From Baseline in Overall Satisfaction at 12 Weeks	SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to overall satisfactory attempts.	from baseline up to 12 weeks of treatment	No
Secondary	Change in Percentage From Baseline in Ability to Ejaculate at 12 Weeks	SEP items success rates are the percentage of all valid and successful intercourse attempts (items answered 'yes') in relation to all valid attempts. Here the SEP item refers to the ability to have successful ejaculations.	from baseline up to 12 weeks of treatment	No
Secondary	Number of Sexual Attempts Till First Successful Attempt		up to 12 weeks of treatment	No
Secondary	Change From Baseline in Ease With Erection at 12 Weeks or LOCF	Treatment group difference in points on the Treatment Satisfaction Scale (TSS, 0-100 normalized ordinal scores, higher scores indicate greater levels of 'ease with erection', 'erectile functioning satisfaction', 'pleasure of sexual activity', 'satisfaction with orgasm', 'confidence for completion', and 'satisfaction with medication') domain "Ease with Erection" from baseline to Week 12 or LOCF expressed as the least square mean difference.	from baseline up to 12 weeks	No
Secondary	Change From Baseline in Erectile Function Satisfaction at 12 Weeks or LOCF	Treatment group difference in points on the Treatment Satisfaction Scale (TSS, 0-100 normalized ordinal scores, higher scores indicate greater levels of 'ease with erection', 'erectile functioning satisfaction', 'pleasure of sexual activity', 'satisfaction with orgasm', 'confidence for completion', and 'satisfaction with medication') domain " Erectile function satisfaction" from baseline to Week 12 or LOCF expressed as the least square mean difference.	from baseline up to 12 weeks	No
Secondary	Change From Baseline in Pleasure of Sexual Activity at 12 Weeks or LOCF	Treatment group difference in points on the Treatment Satisfaction Scale (TSS, 0-100 normalized ordinal scores, higher scores indicate greater levels of 'ease with erection', 'erectile functioning satisfaction', 'pleasure of sexual activity', 'satisfaction with orgasm', 'confidence for completion', and 'satisfaction with medication') domain " Pleasure of sexual activity" from baseline to Week 12 or LOCF expressed as the least square mean difference.	from baseline up to 12 weeks	No
Secondary	Change From Baseline in Satisfaction With Orgasm at 12 Weeks or LOCF	Treatment group difference in points on the Treatment Satisfaction Scale (TSS, 0-100 normalized ordinal scores, higher scores indicate greater levels of 'ease with erection', 'erectile functioning satisfaction', 'pleasure of sexual activity', 'satisfaction with orgasm', 'confidence for completion', and 'satisfaction with medication') domain "Satisfaction with orgasm" from baseline to Week 12 or LOCF expressed as the least square mean difference.	from baseline up to 12 weeks	No
Secondary	Change From Baseline in Confidence for Completion at 12 Weeks or LOCF	Treatment group difference in points on the Treatment Satisfaction Scale (TSS, 0-100 normalized ordinal scores, higher scores indicate greater levels of 'ease with erection', 'erectile functioning satisfaction', 'pleasure of sexual activity', 'satisfaction with orgasm', 'confidence for completion', and 'satisfaction with medication') domain "Confidence for completion" from baseline to Week 12 or LOCF expressed as the least square mean difference.	from baseline up to 12 weeks	No
Secondary	Satisfaction With Medication at Week 12 or LOCF	Treatment group difference in points on the Treatment Satisfaction Scale (TSS, 0-100 normalized ordinal scores, higher scores indicate greater levels of 'ease with erection', 'erectile functioning satisfaction', 'pleasure of sexual activity', 'satisfaction with orgasm', 'confidence for completion', and 'satisfaction with medication') domain "Satisfaction with medication" at LOCF expressed as the least square mean difference.	up to 12 weeks	No
Secondary	Patient Self Reported Improvement of Erectile Function Under Treatment Using a Categorical Rating Scale	Categorical Rating Scale is a binary rating scale with 2 response options which is 'yes/no'; percentage of participants with positive answers to the Global Assessment Question. Global Assessment Question (GAQ): 'Has the treatment you have been taking over the past for weeks improved your erection?' (yes/no)	up to 12 weeks of treatment	No
Secondary	Pharmacokinetics Measured as Area Under Curve (AUC) of Vardenafil in Plasma	Plasma concentrations after single dose administration of 10 mg Vardenafil ODT followed for up to 24 hours post-dose.	Visit 5 after 12 weeks of treatment	No
Secondary	Pharmacokinetics Measured as Maximum Concentration (Cmax) of Vardenafil in Plasma	Plasma concentrations after single dose administration of 10 mg Vardenafil ODT followed for up to 24 hours post-dose.	Visit 5 after 12 weeks of treatment	No
Secondary	Pharmacokinetics Measured as Area Under Curve (AUC) of Metabolite M-1 (BAY44-5576) in Plasma	Plasma concentrations after single dose administration of 10 mg Vardenafil ODT followed for up to 24 hours post-dose.	Visit 5 after 12 weeks of treatment	No
Secondary	Pharmacokinetics Measured as Maximum Concentration (Cmax) of Metabolite M-1 (BAY44-5576) in Plasma	Plasma concentrations after single dose administration of 10 mg Vardenafil ODT followed for up to 24 hours post-dose.	Visit 5 after 12 weeks of treatment	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information of Bayer products for Europe
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer Healthcare products.